HbA1c Reduction, Not Weight Loss, Drives GLP-1RA Heart Benefits
Emma Harutyunyan, Endocrinologist at Yeolyan Hematology and Oncology Center, shared a post by Daisuke Yabe on LinkedIn:
”HbA1c reduction, not bodyweight change, was significantly and proportionally associated with MACE risk reduction.
HbA1c lowering may serve as a useful surrogate for the cardiovascular improvements associated with GLP-1RAs in type 2 diabetes.”
Quoting Daisuke Yabe‘s post:
”FYI”
Title: Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials
Authors: Masashi Hasebe, Chen-Yang Su, Yamato Keidai, Hiroto Minamino, Daisuke Yabe, Nobuya Inagaki, Satoshi Yoshiji
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 18:38Maia Meier: Muhiba’s Story of Courage, Resilience and Hope With Type 3 VWD
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
-
Aug 26, 2026, 18:24New Educational Content for the Bleeding Disorders Community – EAHAD
-
Aug 26, 2026, 18:14N. Mariana S. Vasquez: From Skin and Gut to Celiac Disease
-
Aug 26, 2026, 18:13Francesca Granata: What Happens When Patients Become Researchers and Researchers Become Advocates?
-
Aug 26, 2026, 18:11Maxima Mendez: Statins Are No Longer the Whole Story
-
Aug 26, 2026, 18:06Ashkan Shoamanesh: ANNEXa-I Analyses Inform Individualized Treatment in Intracranial Hemorrhage
-
Aug 26, 2026, 18:01Sam Tsimikas: Lp(a) and Oxidized Phospholipids Reveal a New Link Between Hypercoagulability and Stronger Clot Formation
-
Aug 26, 2026, 17:52Kamlesh Darji: A Practical Guide to Interpreting Coagulation Tests